• linkedin
  • Increase Font
  • Sharebar

    Study: HCV week 4 viral load predicts DAA treatment response

    The hepatitis C virus (HCV) viral load after four weeks of treatment with direct-acting antiviral (DAA) agents predicts sustained virologic response (SVR) in a real-world clinical setting, according to a new study.

    “The results support the use of 8-week sofosbuvir/ledipasvir regimens in a selected subgroup of patients  with genotype 1 infection without cirrhosis who are treatment-naive and have a baseline viral load less than 6 million,” senior author George Ioannou, MD, associate professor of medicine at the University of Washington in Seattle, told Medical Economics.

    The researchers published their results online October 12, 2017, in Journal of Viral Hepatitis.

    They identified 21,095 patients who initiated DAA-based antiviral treatment in the national Veterans Affairs (VA) healthcare system from January 1, 2014, to June 30, 2015. Week 4 viral load was undetectable in 36.1% of patients, detectable below quantification in 45.6%, detectable above quantification with viral load up to 42 IU/mL in 9.3% and detectable above quantification with viral load above 42 IU/mL in 9.1%.

    Those with detectable below quantification (SVR=91.8%), detectable above quantification up to 42 (SVR=90.0%) and detectable above quantification above 42 (SVR=86.2%) had progressively lower likelihood of achieving SVR after adjusting for baseline characteristics and treatment duration as compared to patients with undetectable week 4 viral load (SVR=93.5%).

    “A positive week 4 viral load is much more common than we previously thought from what was reported in clinical trials, and is associated with failure to achieve SVR,” said Ioannou. “A surprising finding was that a positive week 4 viral load was so much more common with the Abbott than with the Roche assays. It is unclear whether this is due to a greater true-positive rate or a greater false-positive rate, or both.”

    Next: Should viral loads affect treatment?

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    Poll